Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
E Miyauchi, S Morita, A Nakamura, Y Hosomi… - Journal of clinical …, 2022 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR
E Miyauchi, S Morita, A Nakamura… - Journal of Clinical …, 2022 - tohoku.elsevierpure.com
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
E Miyauchi, S Morita, A Nakamura… - Journal of Clinical …, 2022 - ingentaconnect.com
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
E Miyauchi, S Morita, A Nakamura, Y Hosomi… - Journal of Clinical …, 2022 - cir.nii.ac.jp
抄録< jats: p> Clinical trials frequently include multiple end points that mature at different
times. The initial report, typically based on the primary end point, may be published when …
times. The initial report, typically based on the primary end point, may be published when …
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
E Miyauchi, S Morita, A Nakamura… - Journal of Clinical …, 2022 - europepmc.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR
E Miyauchi, S Morita, A Nakamura, Y Hosomi… - 2022 - pubmed.ncbi.nlm.nih.gov
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …
[HTML][HTML] Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
E Miyauchi, S Morita, A Nakamura… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …